The race for innovative drugs has become a defining front in US-China competition. While the United States continues to lead in original drug innovation, China is rapidly advancing through strategic investment, scale, and efficiency, reshaping the future of global pharmaceutical development.
How will geopolitical competition shape the next phase of drug innovation, and what does it mean for patients, researchers, and health systems worldwide?
Hear from Prof Ong Choon Nam as he delves into how innovative drugs have become a strategic asset in US-China rivalry, and how policy, regulation, talent, and industrial strategy are increasingly intertwined with global health innovation and access.